Platelets are anucleate cells produced by megakaryocytes. In recent years, a robust body of
literature supports the evolving role of platelets as key sentinel and effector cells in infectious …

During the last decade, the development of improved and novel approaches for the
treatment of hemophilia A has expanded tremendously. These approaches include factor …

Background Efanesoctocog alfa provides high sustained factor VIII activity by overcoming
the von Willebrand factor–imposed half-life ceiling. The efficacy, safety, and …

Background Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with
superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously …

Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked
bleeding disorders. Replacement therapy has been the cornerstone of the management of …

Abstract von Willebrand disease (VWD) is the most common inherited bleeding disorder.
The disorder is characterized by excessive mucocutaneous bleeding. The most common …

Hemophilia A (HA) and hemophilia B (HB) are the most common severe bleeding disorders.
Replacement therapy, providing the missing coagulation factor, has been the mainstay of …

Background Factor VIII replacement products have improved the care of patients with
hemophilia A, but the short half-life of these products affects the patients' quality of life. The …

Haemophilia is a rare disease for which the approved therapeutic options have remained
virtually unchanged for 50 years. In the past decade, however, there has been an explosion …

Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A.
Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates …